Warning: The NCBI web site requires JavaScript to function. more...
The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A, Hegardt C.
Breast Cancer Res. 2008;10(3):R53. Epub 2008 Jun 17.
Related citations
Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K, McMichael N, Berglund P, Honeth G, Hegardt C, Rydén L, Luts L, Bendahl PO, Hedenfalk I.
Breast Cancer Res Treat. 2010 Jul;122(2):315-24. Epub 2009 Oct 1.
Breast cancer stem cells and intrinsic subtypes: controversies rage on.
Nakshatri H, Srour EF, Badve S.
Curr Stem Cell Res Ther. 2009 Jan;4(1):50-60. Review.
Tumor-endothelial interaction links the CD44(+)/CD24(-) phenotype with poor prognosis in early-stage breast cancer.
Buess M, Rajski M, Vogel-Durrer BM, Herrmann R, Rochlitz C.
Neoplasia. 2009 Oct;11(10):987-1002.
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics.
Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV, Varticovski L.
Breast Cancer Res. 2008;10(1):R10. Epub 2008 Feb 1.
Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells.
Pommier SJ, Quan GG, Christante D, Muller P, Newell AE, Olson SB, Diggs B, Muldoon L, Neuwelt E, Pommier RF.
Ann Surg Oncol. 2010 Feb;17(2):613-23. Epub 2009 Oct 17.
Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F, Paredes J.
J Clin Pathol. 2011 Nov;64(11):937-46. Epub 2011 Jun 16.
CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.
Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H.
Breast Cancer Res. 2006;8(5):R59.
A novel mouse model of human breast cancer stem-like cells with high CD44+CD24-/lower phenotype metastasis to human bone.
Ling LJ, Wang S, Liu XA, Shen EC, Ding Q, Lu C, Xu J, Cao QH, Zhu HQ, Wang F.
Chin Med J (Engl). 2008 Oct 20;121(20):1980-6.
Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufí S, Del Barco S, Lopez-Bonet E, Brunet J, Menendez JA.
Biochem Biophys Res Commun. 2010 Jun 18;397(1):27-33. Epub 2010 May 12.
Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.
Tanei T, Morimoto K, Shimazu K, Kim SJ, Tanji Y, Taguchi T, Tamaki Y, Noguchi S.
Clin Cancer Res. 2009 Jun 15;15(12):4234-41. Epub 2009 Jun 9.
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype.
Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ.
Clin Cancer Res. 2006 Oct 1;12(19):5615-21.
Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis.
Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H.
Clin Cancer Res. 2005 Feb 1;11(3):1154-9.
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.
Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Fernö M, Isola J.
Breast Cancer Res. 2007;9(1):R16.
The clinicopathological significance of CD44+/CD24-/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast.
Li W, Liu F, Lei T, Xu X, Liu B, Cui L, Wei J, Guo X, Lang R, Fan Y, Gu F, Tang P, Zhang X, Fu L.
Pathol Res Pract. 2010 Dec 15;206(12):828-34. Epub 2010 Oct 24.
Phenotypic characterization of mammosphere-forming cells from the human MA-11 breast carcinoma cell line.
Rappa G, Lorico A.
Exp Cell Res. 2010 May 15;316(9):1576-86. Epub 2010 Jan 11.
The CD44+/CD24- phenotype relates to 'triple-negative' state and unfavorable prognosis in breast cancer patients.
Giatromanolaki A, Sivridis E, Fiska A, Koukourakis MI.
Med Oncol. 2011 Sep;28(3):745-52. Epub 2010 Apr 20.
CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.
Olsson E, Honeth G, Bendahl PO, Saal LH, Gruvberger-Saal S, Ringnér M, Vallon-Christersson J, Jönsson G, Holm K, Lövgren K, Fernö M, Grabau D, Borg A, Hegardt C.
BMC Cancer. 2011 Sep 29;11:418.
CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.
Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL.
Br J Cancer. 2008 Feb 26;98(4):756-65. Epub 2008 Feb 12.
CD44(+)/CD24(-) cells are transit progenitors and do not determine the molecular subtypes and clinical parameters in breast carcinomas.
Lü X, Xu K, Lü H, Yin Y, Ma C, Liu Y, Li H, Suo Z.
Ultrastruct Pathol. 2011 Apr;35(2):72-8.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on